Eyewire News: The Podcast | Podcast Guru

Recent Episodes

Kodiak Plans to Submit BLA for Zenkuda After Phase 3 Data

Kodiak Sciences meets its primary endpoint in a phase 3 trial for its DME drug candidate clearing the way for a regulatory submission; the European Commission approves Roche’s Susvimo for wet AMD; and Merck announces topline results from a pivotal phase 2b/3 trial evaluating two doses of its DME treatment candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices

6 MIN

Breaking News From the ESCRS Congress in London (Part 2 of 2)

EyewireTV reports on new products and breaking news live from the ESCRS Congress in London. Learn more about your ad choices. Visit megaphone.fm/adchoices

8 MIN

Breaking News From the ESCRS Congress in London (Part 1 of 2)

EyewireTV reports on new products and breaking news live from the ESCRS Congress in London. Learn more about your ad choices. Visit megaphone.fm/adchoices

10 MIN

FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA

The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US. Learn more about your ad choices. Visit megaphone.fm/adchoices

4 MIN

FDA Sets PDUFA Date for Investigational Glaucoma Eye Drop

The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA). Learn more about your ad choices. Visit megaphone.fm/adchoices

6 MIN